Area of research
Cardiology and Cardiovascular Medicine · Internal Medicine
Research interest
Research interests include Atrial Fibrillation Management and Outcomes, Cardiac Arrhythmias and Treatments, Antiplatelet Therapy and Cardiovascular Diseases, and Venous Thromboembolism Diagnosis and Management.
Residual Stroke Risk Among Patients With Atrial Fibrillation Prescribed Oral Anticoagulants: A Patient‐Level Meta‐Analysis From COMBINE AF
Shared decision-making in atrial fibrillation: patient-reported involvement in treatment decisions
Risk of major cardiovascular and neurologic events with obstructive sleep apnea among patients with atrial fibrillation
Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation
Evaluation of the Age, Biomarkers, and Clinical History–Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials
Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation
Blood Pressure Control and Cardiovascular Outcomes in Patients With Atrial Fibrillation (From the ORBIT-AF Registry)
Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II
Frequency and Outcomes of Reduced Dose Non–Vitamin K Antagonist Anticoagulants: Results From ORBIT‐AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)
B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation
Screening for Atrial Fibrillation
International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries
Association of of Atrial Fibrillation Clinical Phenotypes With Treatment Patterns and Outcomes
A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score
Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial
The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study
Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2
Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation
North American Thrombosis Forum, AF Action Initiative Consensus Document
Changes in Renal Function in Patients With Atrial Fibrillation
Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial
Comparison of Characteristics and Outcomes of Dabigatran Versus Warfarin in Hypertensive Patients With Atrial Fibrillation (from the RE-LY Trial)
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation
Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: Findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation
Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin